Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential

Journal of Cardiovascular Pharmacology

Volumn 26, Issue 5, 1995, Pages 803-809

  Grand, Bruno Le ^a   Talmant, Jean Michel ^a   Rieu, Jean Pierre ^a   Patoiseau, Jean François ^a   Colpaert, Francis C ^a   John, Gareth W ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Action potential duration; Benzoyl piperidine; Ketanserin; Potassium currents; Serotonin (5 HT)2A 2C receptors

Indexed keywords

2 [(2 DIMETHYLAMINO 2 METHYLPROPYL)THIO] 3 PHENYLQUINOLINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; KETANSERIN TARTRATE; PENTOBARBITAL; PIPERIDINE DERIVATIVE; PIRENPERONE; POTASSIUM CHANNEL; RITANSERIN; SEROTONIN 1C RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GUINEA PIG; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL;

ACTION POTENTIALS; AMPHETAMINES; ANIMAL; GUINEA PIGS; HEART; KETANSERIN; MALE; PIPERIDINES; POTASSIUM CHANNELS; SEROTONIN ANTAGONISTS;

EID: 0028868956     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199511000-00018     Document Type: Article

References (22)

1. Cameron HA, Waller PC, Ramsay LE. Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or ß-adrenoceptor antagonist. Br J Clin Pharmacol 1987:24:705-11.
2. Zehender M, Meinertz T, Hohnloser S, et al. The multicenter ketanserin research group. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 1989:63:826-32.
3. Damiano BP, Rosen MR. Effects of pacing on triggered activity induced by early afterdepolarizations. Circulation 1984:69:1013-25.
4. Saman S, Thandroyen F, Opie LH. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias. J Cardiovasc Pharmacol 1985:7(suppl 7):S70-5.
5. Kamiya K, Venkatesh N, Singh BN. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: particular reference to repolarization. Am Heart J 1988:115:1222-8.
6. Zaza A, Malfatto G, Rosen MR. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. J Pharmacol Ther Exp 1989:250:397-405.
7. Zhang ZH, Boutjdir M, El-Sherif N. Ketanserin inhibits depolarization-activated outward potassium current in rat ventricular myocytes. Circ Res 1994:75:711-21.
8. Le Grand B, Marty A, Colpaert FC, John GW. Ketanserin inhibits the transient outward current in rabbit ventricular myocytes. J Cardiovasc Pharmacol 1995:25:341-4.
9. Mitra R, Morad M. A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am J Physiol 1985;249:H1056-60.
10. Marquardt DW. An algorithm for least squares estimation of non-linear parameters. J Soc Indust Appl Math 1963;11:431.
11. Colpaert FC, Niemegeers CJE, Janssen PAJ. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxy-tryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther 1982:221:206-14.
12. Colpaert FC, Meert TF, Niemegeers CJE, Janssen PAJ. Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology 1985:86:45-54.
13. Blackburn TP, Thornber CV, Pearce RJ, Cox B. In vitro pharmacology of ICI 170809, a new 5-HT, antagonist. FASEB J 1988;2:A1404 (P6441).
14. 2 binding characteristics of l-(2.5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem 1986:29:194-9.
15. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity of low quinidine concentrations in canine Purkinje fibers. Circ Res 1985:56:857-67.
16. Nattel S, Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984:229:283-91.
17. Knilans TK, Lathrop DA, Nanasi PP, Schwartz A, Varro A. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax. Br J Pharmacol 1991:103:1568-72.
18. Colatsky TJ. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. Circ Res 1982:50:17-27.
19. K blocking drug, UK-68.798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990:16:401-10.
20. Sanguinetti MC. Modulation of potassium channels by anti-arrhythmic and antihypertensive drugs. Hypertension 1992:19:228-36.
21. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea-pig myocytes: mechanism of action. Circ Res 1991:68:77-84.
22. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J 1993:14(suppl H):3-13.